Creative Planning
VYGR icon

Creative Planning’s Voyager Therapeutics VYGR Stock Holding History

Creative Planning’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,499
Closed -$99.2K – 3743
2024
Q4 		$99.2K Buy
+17,499
New +$113K ﹤0.01% 3157

Other funds holding VYGR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Creative Planning's VYGR Position: Q1 2025 in Review

Creative Planning sold out of Voyager Therapeutics (VYGR) in Q1 2025, closing a stake of 17,499 shares — an estimated $99.2K sold.

Creative Planning first reported a position in VYGR in Q4 2024 and held it in 1 quarter. The position peaked at $99.2K in Q4 2024. 116 funds tracked by Wall St. Rank hold VYGR as of Q1 2025.

  • Creative Planning reported no remaining Voyager Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Creative Planning sold 17,499 Voyager Therapeutics shares in Q1 2025, an estimated $99.2K.
  • Creative Planning first reported a position in Voyager Therapeutics in Q4 2024 and held it in 1 quarter.
  • Creative Planning's Voyager Therapeutics position peaked at $99.2K in Q4 2024.
  • 116 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2025.

Based on Creative Planning's 13F filing for Q1 2025, filed 15 May 2025.